Algorae Pharmaceuticals Issues 90 Million Performance Rights as Director Remuneration on 11 November 2026

Mukul

11 November 2026 06:04 PM AEDT

Algorae Pharmaceuticals Issues 90 Million Performance Rights as Director Remuneration on 11 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Algorae Pharmaceuticals Limited (ASX:1AI) has issued 90,000,000 unquoted performance rights on 11 November 2026, with the securities forming an incentive-based component of directors' remuneration, according to an Appendix 3G filing lodged with the ASX.

Key Points

90,000,000 performance rights (ASX code: 1AIAS) were issued on 11 November 2026
The securities were not issued for cash consideration, but as an incentive-based component of directors' remuneration
The performance rights are unquoted and are not intended to be quoted on ASX
Following the issue, total unquoted performance rights on issue stand at 259,000,000

Performance Rights Issue Details

Algorae Pharmaceuticals issued 90,000,000 performance rights carrying the ASX security code 1AIAS on 11 November 2026. The filing confirms the securities were not issued for cash consideration. Instead, the company disclosed that the securities were issued as an incentive-based component of directors' remuneration. The issue was previously notified to the market through an Appendix 3B lodged on 10 November 2026, and the filing states there are no further issues of securities yet to take place to complete the transaction referred to in that Appendix 3B.

Unquoted and Quoted Securities on Issue

Following the issue of the performance rights, Algorae Pharmaceuticals' securities on issue comprise 2,027,570,988 ordinary fully paid shares (ASX:1AI) in the quoted class. In the unquoted class, the company has 259,000,000 performance rights (1AIAS) and 376,423,855 options expiring 1 December 2029 at an exercise price of $0.014 (1AIAT) on issue. The filing notes that the figures for securities on issue are automatically generated and may not reflect the entity's current issued capital if other forms are currently with ASX for processing.

Transaction Background and Classification

The Appendix 3G filing, dated 11 November 2026, relates to a transaction classified as a placement or other type of issue, as identified in the corresponding Appendix 3B lodged on 10 November 2026. The performance rights are categorised as an existing security class under ASX code 1AIAS. The filing was submitted as a new announcement by Algorae Pharmaceuticals Limited, which holds Australian Business Number 14104028042. The securities issued are not intended to be quoted on ASX.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.